Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sinohealth Holdings's share price for the quarter that ended in Jun. 2024 was HK$5.03. Sinohealth Holdings's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 409.1 Mil. Therefore, Sinohealth Holdings's market cap for the quarter that ended in Jun. 2024 was HK$2,057.7 Mil.
Sinohealth Holdings's quarterly market cap
increased
from Jun. 2023 (HK$2,064.1 Mil) to Dec. 2023 (HK$2,303.0 Mil) but then
declined
from Dec. 2023 (HK$2,303.0 Mil) to Jun. 2024 (HK$2,057.7 Mil).
Sinohealth Holdings's annual market cap
increased
from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$2,371.5 Mil) but then
declined
from Dec. 2022 (HK$2,371.5 Mil) to Dec. 2023 (HK$2,303.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinohealth Holdings's Enterprise Value for Today is HK$673.1 Mil.
Sinohealth Holdings Market Cap Historical Data
The historical data trend for Sinohealth Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinohealth Holdings's Market Cap
For the Health Information Services subindustry, Sinohealth Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinohealth Holdings's Market Cap Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sinohealth Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinohealth Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sinohealth Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinohealth Holdings (HKSE:02361) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinohealth Holdings Market Cap Related Terms
Thank you for viewing the detailed overview of Sinohealth Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinohealth is a leading provider of Big Data and artificial intelligence-based marketing and distribution information tools, including SaaS-based customer relationship management solutions to mainland China medical product manufacturers. It sources retail data through pharmacy partnerships and provides data analysis to the pharmaceutical and corporate clients it serves. Since its establishment in 2007, its focus has been on building a strong Big Data engine and networking capabilities to assist clients in their product investments and sales and marketing strategies. It is now launching various cloud-based systems and platform solutions for its clients and expanding its SaaS products, which are expected to be the key growth driver in future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02361 has been successfully added to your 